{"pmid":32308266,"pmcid":"PMC7147498","title":"Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.","text":["Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus.","Design and development of an effective drug to combat the 2019 novel coronavirus remains a challenge. Therefore, it is of interest to study the binding features of 1615 FDA approved drugs with the recently known 2019-nCoV main protease structure having high sequence homology with that from SARS-CoV. We document the binding features of top 10 drugs with the target protein. We further report that Conivaptan and Azelastine are mainly involved in hydrophobic interactions with active site residues. Both drugs can maintain close proximity to the binding pocket of main protease during simulation. However, these data need further in vitro and in vivo evaluation to repurpose these two drugs against 2019-nCoV.","Bioinformation","Odhar, Hasanain Abdulhameed","Ahjel, Salam Waheed","Albeer, Ali A Mohammed Ali","Hashim, Ahmed Fadhil","Rayshan, Ali Mahmood","Humadi, Suhad Sami","32308266"],"abstract":["Design and development of an effective drug to combat the 2019 novel coronavirus remains a challenge. Therefore, it is of interest to study the binding features of 1615 FDA approved drugs with the recently known 2019-nCoV main protease structure having high sequence homology with that from SARS-CoV. We document the binding features of top 10 drugs with the target protein. We further report that Conivaptan and Azelastine are mainly involved in hydrophobic interactions with active site residues. Both drugs can maintain close proximity to the binding pocket of main protease during simulation. However, these data need further in vitro and in vivo evaluation to repurpose these two drugs against 2019-nCoV."],"journal":"Bioinformation","authors":["Odhar, Hasanain Abdulhameed","Ahjel, Salam Waheed","Albeer, Ali A Mohammed Ali","Hashim, Ahmed Fadhil","Rayshan, Ali Mahmood","Humadi, Suhad Sami"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32308266","week":"202017|Apr 20 - Apr 26","doi":"10.6026/97320630016236","keywords":["2019-ncov","docking","dynamics simulation","main protease","repurposing"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["conivaptan","azelastine"],"_version_":1664632501440610304,"score":8.518259,"similar":[{"pmid":32251634,"title":"Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.","text":["Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease.","AIMS: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. MATERIALS AND METHODS: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. KEY FINDINGS: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. SIGNIFICANCE: The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment.","Life Sci","Kandeel, Mahmoud","Al-Nazawi, Mohammed","32251634"],"abstract":["AIMS: In December 2019, the Coronavirus disease-2019 (COVID-19) virus has emerged in Wuhan, China. In this research, the first resolved COVID-19 crystal structure (main protease) was targeted in a virtual screening study by of FDA approved drugs dataset. In addition, a knowledge gap in relations of COVID-19 with the previously known fatal Coronaviruses (CoVs) epidemics, SARS and MERS CoVs, was covered by investigation of sequence statistics and phylogenetics. MATERIALS AND METHODS: Molecular modeling, virtual screening, docking, sequence comparison statistics and phylogenetics of the COVID-19 main protease were investigated. KEY FINDINGS: COVID-19 Mpro formed a phylogenetic group with SARS CoV that was distant from MERS CoV. The identity% was 96.061 and 51.61 for COVID-19/SARS and COVID-19/MERS CoV sequence comparisons, respectively. The top 20 drugs in the virtual screening studies comprised a broad-spectrum antiviral (ribavirin), anti-hepatitis B virus (telbivudine), two vitamins (vitamin B12 and nicotinamide) and other miscellaneous systemically acting drugs. Of special interest, ribavirin had been used in treating cases of SARS CoV. SIGNIFICANCE: The present study provided a comprehensive targeting of the first resolved COVID+19 structure of Mpro and found a suitable save drugs for repurposing against the viral Mpro. Ribavirin, telbivudine, vitamin B12 and nicotinamide can be combined and used for COVID treatment. This initiative relocates already marketed and approved safe drugs for potential use in COVID-treatment."],"journal":"Life Sci","authors":["Kandeel, Mahmoud","Al-Nazawi, Mohammed"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251634","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.lfs.2020.117627","keywords":["2019-Novel Coronavirus","COVID-19, 2019-nCoV","Main protease","Molecular modeling","Wuhan Coronavirus"],"source":"PubMed","locations":["COVID+19","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352136214249472,"score":298.7962},{"pmid":32315171,"title":"Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study.","text":["Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study.","The recent outbreak of novel coronavirus disease -19 (COVID-19) calls for and welcomes possible treatment strategies using drugs on the market. It is very efficient to apply computer-aided drug design techniques to quickly identify promising drug repurposing candidates, especially after the detailed 3D-structures of key virous proteins are resolved. The virus causing COVID-19 is SARS-Cov-2. Taking the advantage of a recently released crystal structure of SARS-Cov-2 main protease in complex with a covalently-bonded inhibitor, N3,1 I conducted virtual docking screening of approved drugs and drug candidates in clinical trials. For the top docking hits, I then performed molecular dynamics simulations followed by binding free energy calculations using an endpoint method called MM-PBSA-WSAS (Molecular Mechanics-Poisson Boltzmann Surface Area-Weighted Solvent-Accessible Surface Area).2-4 Several promising known drugs stand out as potential inhibitors of SARS-Cov-2 main protease, including Carfilzomib, Eravacycline, Valrubicin, Lopinavir and Elbasvir. Carfilzomib, an approved anti-cancer drug acting as a proteasome inhibitor, has the best MM-PBSA-WSAS binding free energy, -13.8 kcal/mol. The second-best repurposing drug candidate, eravacycline, is synthetic halogenated tetracycline class antibiotic. Streptomycin, another antibiotic and a charged molecule, also demonstrates some inhibitory effect, even though the predicted binding free energy of the charged form (-3.8 kcal/mol) is not nearly as low as that of the neutral form (-7.9 kcal/mol). One bioactive, PubChem 23727975, has a binding free energy of -12.9 kcal/mol. Detailed receptor-ligand interactions were analyzed and hot spots for the receptor-ligand binding were identified. I found that one hotspot residue HIS41, is a conserved residue across many viruses including SARS-Cov, SARS-Cov-2, MERS-Cov, and HCV. The findings of this study can facilitate rational drug design targeting the SARS-Cov-2 main protease.","J Chem Inf Model","Wang, Junmei","32315171"],"abstract":["The recent outbreak of novel coronavirus disease -19 (COVID-19) calls for and welcomes possible treatment strategies using drugs on the market. It is very efficient to apply computer-aided drug design techniques to quickly identify promising drug repurposing candidates, especially after the detailed 3D-structures of key virous proteins are resolved. The virus causing COVID-19 is SARS-Cov-2. Taking the advantage of a recently released crystal structure of SARS-Cov-2 main protease in complex with a covalently-bonded inhibitor, N3,1 I conducted virtual docking screening of approved drugs and drug candidates in clinical trials. For the top docking hits, I then performed molecular dynamics simulations followed by binding free energy calculations using an endpoint method called MM-PBSA-WSAS (Molecular Mechanics-Poisson Boltzmann Surface Area-Weighted Solvent-Accessible Surface Area).2-4 Several promising known drugs stand out as potential inhibitors of SARS-Cov-2 main protease, including Carfilzomib, Eravacycline, Valrubicin, Lopinavir and Elbasvir. Carfilzomib, an approved anti-cancer drug acting as a proteasome inhibitor, has the best MM-PBSA-WSAS binding free energy, -13.8 kcal/mol. The second-best repurposing drug candidate, eravacycline, is synthetic halogenated tetracycline class antibiotic. Streptomycin, another antibiotic and a charged molecule, also demonstrates some inhibitory effect, even though the predicted binding free energy of the charged form (-3.8 kcal/mol) is not nearly as low as that of the neutral form (-7.9 kcal/mol). One bioactive, PubChem 23727975, has a binding free energy of -12.9 kcal/mol. Detailed receptor-ligand interactions were analyzed and hot spots for the receptor-ligand binding were identified. I found that one hotspot residue HIS41, is a conserved residue across many viruses including SARS-Cov, SARS-Cov-2, MERS-Cov, and HCV. The findings of this study can facilitate rational drug design targeting the SARS-Cov-2 main protease."],"journal":"J Chem Inf Model","authors":["Wang, Junmei"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32315171","week":"202017|Apr 20 - Apr 26","doi":"10.1021/acs.jcim.0c00179","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664714520124194816,"score":245.23372},{"pmid":32238094,"title":"Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach.","text":["Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2 via integrated computational approach.","Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs (Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.Communicated by Ramaswamy H. Sarma.","J Biomol Struct Dyn","Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer","32238094"],"abstract":["Recently, the world has witnessed outbreak of a novel Coronavirus (SARS-CoV-2), the virus which initially emerged in Wuhan, China has now made its way to a large part of the world, resulting in a public emergency of international concern. The functional importance of Chymotrypsin-like protease (3CL(pro)) in viral replication and maturation turns it into an attractive target for the development of effective antiviral drugs against SARS and other coronaviruses. At present, there is no standard drug regime nor any vaccine available against the infection. The rapid development and identification of efficient interventions against SARS-CoV-2 remains a major challenge. Based on the available knowledge of closely related coronavirus and their safety profiles, repurposing of existing antiviral drugs and screening of available databases is considered a near term strategic and economic way to contain the SARS-CoV-2 pandemic. Herein, we applied computational drug design methods to identify Chymotrypsin-like protease inhibitors from FDA approved antiviral drugs and our in-house database of natural and drug-like compounds of synthetic origin. As a result three FDA approved drugs (Remdesivir, Saquinavir and Darunavir) and two natural compounds (. flavone and coumarine derivatives) were identified as promising hits. Further, MD simulation and binding free energy calculations were performed to evaluate the dynamic behavior, stability of protein-ligand contact, and binding affinity of the hit compounds. Our results indicate that the identified compounds can inhibit the function of Chymotrypsin-like protease (3CL(pro)) of Coronavirus. Considering the severity of the spread of coronavirus, the current study is in-line with the concept of finding the new inhibitors against the vital pathway of the corona virus to expedite the process of drug discovery.Communicated by Ramaswamy H. Sarma."],"journal":"J Biomol Struct Dyn","authors":["Khan, Salman Ali","Zia, Komal","Ashraf, Sajda","Uddin, Reaz","Ul-Haq, Zaheer"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238094","week":"202014|Mar 30 - Apr 05","doi":"10.1080/07391102.2020.1751298","keywords":["3clpro","md simulation","sars-cov-2","corona virus","drug repurposing","remdesivir","virtual screening"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"locations":["Wuhan","China","Chymotrypsin","Chymotrypsin"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["flavone","remdesivir","Coumarins","Darunavir","Saquinavir"],"_version_":1664638354245812224,"score":231.98758},{"pmid":32318328,"pmcid":"PMC7169934","title":"D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19.","text":["D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19.","A highly effective medicine is urgently required to cure coronavirus disease 2019 (COVID-19). For the purpose, we developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies, the other is for identifying lead compounds against potential drug targets via docking. This server has its unique features, (1) the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible; (2) all the potential ligand-binding sites with volume larger than 200 A(3) on a protein structure were identified for docking; (3) correlation information among some conformations or binding sites was annotated; (4) it is easily to be updated, and is accessible freely to public (https://www.d3pharma.com/D3Targets-2019-nCoV/index.php). Currently, the webserver contains 42 proteins [20 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) encoded proteins and 22 human proteins involved in virus infection, replication and release] with 69 different conformations/structures and 557 potential ligand-binding pockets in total. With 6 examples, we demonstrated that the webserver should be useful to medicinal chemists, pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19.","Acta Pharm Sin B","Shi, Yulong","Zhang, Xinben","Mu, Kaijie","Peng, Cheng","Zhu, Zhengdan","Wang, Xiaoyu","Yang, Yanqing","Xu, Zhijian","Zhu, Weiliang","32318328"],"abstract":["A highly effective medicine is urgently required to cure coronavirus disease 2019 (COVID-19). For the purpose, we developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies, the other is for identifying lead compounds against potential drug targets via docking. This server has its unique features, (1) the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible; (2) all the potential ligand-binding sites with volume larger than 200 A(3) on a protein structure were identified for docking; (3) correlation information among some conformations or binding sites was annotated; (4) it is easily to be updated, and is accessible freely to public (https://www.d3pharma.com/D3Targets-2019-nCoV/index.php). Currently, the webserver contains 42 proteins [20 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) encoded proteins and 22 human proteins involved in virus infection, replication and release] with 69 different conformations/structures and 557 potential ligand-binding pockets in total. With 6 examples, we demonstrated that the webserver should be useful to medicinal chemists, pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19."],"journal":"Acta Pharm Sin B","authors":["Shi, Yulong","Zhang, Xinben","Mu, Kaijie","Peng, Cheng","Zhu, Zhengdan","Wang, Xiaoyu","Yang, Yanqing","Xu, Zhijian","Zhu, Weiliang"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32318328","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.apsb.2020.04.006","keywords":["covid-19","d3targets-2019-ncov","multi-conformation","multi-site","sars-cov-2","target prediction","docking"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087685206016,"score":230.65715},{"pmid":32293875,"title":"Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019?: Atomistic insights into the inhibitory mechanisms.","text":["Why are lopinavir and ritonavir effective against the newly emerged Coronavirus 2019?: Atomistic insights into the inhibitory mechanisms.","Since the emergence of a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly reported from Wuhan, China, to date, neither a specific vaccine nor antiviral drug against SARS-CoV-2 is available. However, a combination of two HIV-1 protease inhibitors lopinavir and ritonavir has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CL(pro)). In this work, molecular complexation between each inhibitor and the SARS-CoV-2 3CL(pro) was studied using all-atom molecular dynamics simulations, free energy calculations and pair interaction energy analyses based on the MM/PB(GB)SA and FMO-MP2/PCM/6-31G*. Both anti-HIV drugs interacted well with the residues at the active site of the SARS-CoV-2 3CL(pro). Ritonavir showed somewhat higher atomic contacts, binding efficiency and key binding residues than that of lopinavir in correspondence with slightly less water accessibility at the 3CL(pro) active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via two hydrogen bond formations. The interactions in terms of electrostatics, dispersion and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19.","Biochemistry","Nutho, Bodee","Mahalapbutr, Panupong","Hengphasatporn, Kowit","Pattaranggoon, Nawanwat Chainuwong","Simanon, Nattapon","Shigeta, Yasuteru","Hannongbua, Supot","Rungrotmongkol, Thanyada","32293875"],"abstract":["Since the emergence of a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was firstly reported from Wuhan, China, to date, neither a specific vaccine nor antiviral drug against SARS-CoV-2 is available. However, a combination of two HIV-1 protease inhibitors lopinavir and ritonavir has been found to be effective against SARS-CoV, and both drugs could bind well to the SARS-CoV 3C-like protease (SARS-CoV 3CL(pro)). In this work, molecular complexation between each inhibitor and the SARS-CoV-2 3CL(pro) was studied using all-atom molecular dynamics simulations, free energy calculations and pair interaction energy analyses based on the MM/PB(GB)SA and FMO-MP2/PCM/6-31G*. Both anti-HIV drugs interacted well with the residues at the active site of the SARS-CoV-2 3CL(pro). Ritonavir showed somewhat higher atomic contacts, binding efficiency and key binding residues than that of lopinavir in correspondence with slightly less water accessibility at the 3CL(pro) active site. In addition, only ritonavir could interact with the oxyanion hole residues N142 and G143 via two hydrogen bond formations. The interactions in terms of electrostatics, dispersion and charge transfer played an important role in the drug binding. The obtained results demonstrated how repurposed anti-HIV drugs could be used to combat COVID-19."],"journal":"Biochemistry","authors":["Nutho, Bodee","Mahalapbutr, Panupong","Hengphasatporn, Kowit","Pattaranggoon, Nawanwat Chainuwong","Simanon, Nattapon","Shigeta, Yasuteru","Hannongbua, Supot","Rungrotmongkol, Thanyada"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32293875","week":"202016|Apr 13 - Apr 19","doi":"10.1021/acs.biochem.0c00160","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ritonavir","Water","Lopinavir","4-(3-benzyl-4-(5-(2-fluorophenyl)-ruan-2-ylmethylene)-5-oxo-4,5-dihydropyrazol-1-yl)benzoic acid"],"_version_":1664636192540327938,"score":227.86473}]}